Drug Metabolism and Pharmacokinetics
Online ISSN : 1880-0920
Print ISSN : 1347-4367
ISSN-L : 1347-4367

この記事には本公開記事があります。本公開記事を参照してください。
引用する場合も本公開記事を引用してください。

Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs
Takeshi HirotaShunsuke EguchiIchiro Ieiri
著者情報
ジャーナル フリー 早期公開

論文ID: DMPK-12-RV-085

この記事には本公開記事があります。
詳細
抄録
  Human cytochrome P450 (CYP) is a superfamily of hemoproteins which oxidize a number of endogenous compounds and xenobiotics. The human CYP2C subfamily consists of four members; CYP2C8, CYP2C9, CYP2C18 and CYP2C19. CYP2C9 and CYP2C19 are important drug metabolizing enzymes and together metabolize approximately 20% of therapeutically used drugs. Forty two allelic variants for CYP2C9 and 34 for CYP2C19 have been reported. The frequencies of these variants show marked inter-ethnic variation. The functional consequences of genetic polymorphisms have been examined, and many studies have shown the clinical importance of these polymorphisms. Current evidence suggests that taking the genetically determined metabolic capacity of CYP2C9 and CYP2C19 into account has the potential to improve individual risk/benefit relationships. However, more prospective studies with clinical endpoints are needed before the paradigm of 'personalized medicine' based on the variants can be established. This review summarizes the currently available important information on this topic.
著者関連情報

この記事は最新の被引用情報を取得できません。

© 2012 by The Japanese Society for the Study of Xenobiotics
feedback
Top